Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00685269 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of Eszopiclone With Mild to Moderate Obstructive Sleep Apnea Syndrome (OSAS)

A Phase 2 study, sponsored by Sumitomo Pharma America.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT00685269 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00685269, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the hypnotic efficacy of ezopiclone in subjects with mild to moderate OSAS.

Interventions

  • DRUG Placebo
  • DRUG Eszopiclone

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2003-08
Est. Completion 2004-01
Phase Phase 2

Sponsor

Sumitomo Pharma America

168 total trials

What the Registry Record Tells You About NCT00685269

The ClinicalTrials.gov registry entry for NCT00685269 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00685269 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00685269 about?

NCT00685269 is a clinical study titled "Safety and Efficacy of Eszopiclone With Mild to Moderate Obstructive Sleep Apnea Syndrome (OSAS)". The purpose of this study is to evaluate the hypnotic efficacy of ezopiclone in subjects with mild to moderate OSAS.

What is the current status of trial NCT00685269?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2003-08. Estimated completion is 2004-01.

What interventions are being tested in trial NCT00685269?

The interventions under investigation include: Placebo (DRUG), Eszopiclone (DRUG).

Who is sponsoring clinical trial NCT00685269?

This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.